Advaxis to Present Poster Entitled “Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogene...
November 06 2018 - 8:00AM
Business Wire
Results Show Treatment of Tumor-Bearing Mice
with Axalimogene Filolisbac (AXAL) Leads to Natural Killer Cell
Activation and Other Important Immune-Related Effects
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology
company focused on the discovery, development and commercialization
of immunotherapy products, announces a poster presentation at the
Society for Immunotherapy of Cancer (SITC). The poster, entitled
“Natural killer (NK) cells orchestrate the antitumor activities of
Listeria monocytogenes (Lm)-based immunotherapy,” evaluated the
impact of Lm-based immunotherapy on the activation of NK cells in a
murine model of human papillomavirus (HPV)-associated tumors.
Poster Number P520 will be presented by Sandy Hayes, Ph.D., Sr.
Director, Research - BioMarkers and Immune Monitoring, on Saturday,
November 10, 2018 from 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m.
Eastern time at the 2018 SITC 33rd annual meeting at the Walter E.
Washington Convention Center in Washington, D.C.
“The results demonstrate that AXAL can induce changes in the
tumor microenvironment that promote NK cell activation, establish
cross-talk between dendritic cells (DC cells), NK cells, and can
facilitate trafficking of tumor antigen-specific T cells into the
tumor core which we believe contribute to the antitumor activity of
AXAL,” said Robert G. Petit, Ph.D., Executive Vice President and
Chief Scientific Officer of Advaxis. “The critical role of NK cells
and NK-DC crosstalk is part of the broad-based immunologic profile
associated with Advaxis Lm vectors and their favorable alteration
of the microenvironment for immunotherapy of solid tumors.”
About Axalimogene Filolisbac
Axalimogene filolisbac is a targeted Listeria monocytogenes
(Lm)-based immunotherapy that attacks HPV-associated cancers by
altering a live strain of Lm bacteria to generate
cancer-fighting T cells against cancer antigens while neutralizing
the tumor’s natural protections that guard the tumor
microenvironment from immunologic attack that is currently in Phase
3 clinical testing. In a Phase 2 trial evaluating axalimogene
filolisbac for the treatment of persistent or recurrent metastatic
(squamous or non-squamous cell) carcinoma of the cervix (PRmCC),
the drug candidate showed a 12-month overall survival rate of 38%
in 50 patients. This is a 52% improvement over the 12-month overall
survival rate that was expected in the trial’s patient population
based on prognostic factors.
Axalimogene filolisbac has received Fast Track designation for
adjuvant therapy for high-risk locally advanced cervical cancer
(HRLACC) and a Special Protocol Assessment for the Phase 3 AIM2CERV
trial in HRLACC patients. The immunotherapy has also received
orphan drug designation in three clinical indications.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of proprietary
Lm-based antigen delivery products. These immunotherapies are based
on a platform technology that utilizes live attenuated Listeria
monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion
proteins. These Lm-based strains are believed to be a significant
advancement in immunotherapy as they integrate multiple functions
into a single immunotherapy and are designed to access and direct
antigen presenting cells to stimulate anti-tumor T cell immunity,
activate the immune system with the equivalent of multiple
adjuvants, and simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and preclinical
development: HPV-associated cancers, neoantigen therapy, hotspot
cancer antigens and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop and commercialize the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapies. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2017, and on Form 10-Q for the quarter ended September
30, 2018, which are available at www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law. You are cautioned not to place undue reliance on
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181106005509/en/
Investors:LHA Investor RelationsMiriam Weber Miller,
212-838-3777mmiller@lhai.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024